PURPOSE: Acute graft-versus-host disease (aGVHD) is a major complication of allogeneic bone marrow transplantation. In steroid-refractory aGVHD, mortality is very high. Pentostatin, a potent inhibitor of adenosine deaminase, induces lymphocyte apoptosis and may be useful in the treatment of this condition. PATIENTS AND METHODS: We have conducted a phase I dose escalation study of pentostatin in patients with steroid-refractory aGVHD. Twenty-three patients were enrolled. Starting dose was 1 mg/m2/d by intravenous injection for 3 days. RESULTS: The maximum tolerated dose was found to be 1.5 mg/m2/d. Late infections at the 2-mg/m2/d dose level were believed to be dose limiting toxicities. Lymphopenia was universal, but the neutrophil count was generally not affected. Fevers associated with neutropenia were not observed. Otherwise, the drug was well tolerated, with only modest elevations of liver function tests and thrombocytopenia, each being observed in a single patient. Twenty-two patients were assessable for response, including 14 complete responses (63%) and three partial responses (13%). Median survival after therapy for the group was 85 days (range, 5 to 1,258 days). CONCLUSION: The suggested intravenous dose for a phase II study will be 1.5 mg/m2/d for 3 days. Pentostatin has activity in patients with steroid-refractory aGVHD that is worth exploring in future trials.
PURPOSE: Acute graft-versus-host disease (aGVHD) is a major complication of allogeneic bone marrow transplantation. In steroid-refractory aGVHD, mortality is very high. Pentostatin, a potent inhibitor of adenosine deaminase, induces lymphocyte apoptosis and may be useful in the treatment of this condition. PATIENTS AND METHODS: We have conducted a phase I dose escalation study of pentostatin in patients with steroid-refractory aGVHD. Twenty-three patients were enrolled. Starting dose was 1 mg/m2/d by intravenous injection for 3 days. RESULTS: The maximum tolerated dose was found to be 1.5 mg/m2/d. Late infections at the 2-mg/m2/d dose level were believed to be dose limiting toxicities. Lymphopenia was universal, but the neutrophil count was generally not affected. Fevers associated with neutropenia were not observed. Otherwise, the drug was well tolerated, with only modest elevations of liver function tests and thrombocytopenia, each being observed in a single patient. Twenty-two patients were assessable for response, including 14 complete responses (63%) and three partial responses (13%). Median survival after therapy for the group was 85 days (range, 5 to 1,258 days). CONCLUSION: The suggested intravenous dose for a phase II study will be 1.5 mg/m2/d for 3 days. Pentostatin has activity in patients with steroid-refractory aGVHD that is worth exploring in future trials.
Authors: Julianna V F Roddy; Bradley M Haverkos; Ali McBride; Kathryn M Leininger; Samantha Jaglowski; Sam Penza; Rebecca Klisovic; William Blum; Sumithira Vasu; Craig C Hofmeister; Don M Benson; Leslie A Andritsos; Steven M Devine; Yvonne A Efebera Journal: Leuk Lymphoma Date: 2015-07-03
Authors: Ming J Poi; Craig C Hofmeister; Jeffrey S Johnston; Ryan B Edwards; Buffy S Jansak; David M Lucas; Sherif S Farag; James T Dalton; Steven M Devine; Michael R Grever; Mitch A Phelps Journal: Clin Pharmacokinet Date: 2013-08 Impact factor: 6.447
Authors: Javier Bolaños-Meade; Juan Wu; Brent R Logan; John E Levine; Vincent T Ho; Amin M Alousi; Daniel J Weisdorf; Leo Luznik Journal: Biol Blood Marrow Transplant Date: 2012-12-12 Impact factor: 5.742
Authors: Amin M Alousi; Daniel J Weisdorf; Brent R Logan; Javier Bolaños-Meade; Shelly Carter; Nancy Difronzo; Marcelo Pasquini; Steven C Goldstein; Vincent T Ho; Brandon Hayes-Lattin; John R Wingard; Mary M Horowitz; John E Levine Journal: Blood Date: 2009-05-14 Impact factor: 22.113
Authors: Pamala A Jacobson; Jiayin Huang; Juan Wu; Miae Kim; Brent Logan; Amin Alousi; Michael Grimley; Javier Bolaños-Meade; Vincent Ho; John E Levine; Daniel Weisdorf Journal: Biol Blood Marrow Transplant Date: 2010-03 Impact factor: 5.742
Authors: T Furlong; P Martin; M E D Flowers; F Carnevale-Schianca; R Yatscoff; T Chauncey; F R Appelbaum; H J Deeg; K Doney; R Witherspoon; B Storer; K M Sullivan; R Storb; R A Nash Journal: Bone Marrow Transplant Date: 2009-04-20 Impact factor: 5.483